BOULDER, Colo.--(BUSINESS WIRE)--Nov. 29, 2011--
Array BioPharma Inc. (NASDAQ: ARRY) today announced data will be
presented on two drug candidates, ARRY-520, a KSP inhibitor, and
ARRY-614, a dual p38/Tie2 inhibitor, at the 2011 Annual Meeting of the
American Society of Hematology in San Diego, California.
The abstracts can be accessed through the American Society of Hematology
website, www.hematology.org/Meetings/Annual-Meeting.
The abstract titles are provided below; however, please note that
according to ASH press policies, all data are embargoed until the time
of the beginning of the presentation. After the presentations, the
posters and presentation slides will be available as PDFs on Array's
website at www.arraybiopharma.com.
|
Poster:
|
|
|
ARRY-520 Shows Durable Responses in Patients with
Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation
Study (Publication #1860)
|
|
Date:
|
|
|
Saturday, December 10, 2011
|
|
Time:
|
|
|
5:30–7:30 p.m. PST
|
|
Location:
|
|
|
San Diego Convention Center, Hall GH
|
|
|
|
|
|
|
Oral
Presentation:
|
|
|
Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2
Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk
Myelodysplastic Syndromes (Abstract #118)
|
|
|
|
|
Presenter:
|
|
|
Rami S. Komrokji, M.D., Malignant Hematology, H. Lee Moffitt Cancer
Center & Research Institute
|
|
Date:
|
|
|
Sunday, December 11, 2011
|
|
Time:
|
|
|
5:15 p.m. PST
|
|
Location:
|
|
|
San Diego Convention Center, Room 6CF
|
|
|
|
|
|
|
Poster:
|
|
|
The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent
Activity in Refractory Myeloma: Results From a Phase 2 Trial in
Patients with Relapsed/Refractory Multiple Myeloma (MM)
(Publication #2935)
|
|
Date:
|
|
|
Sunday, December 11, 2011
|
|
Time:
|
|
|
6–8 p.m. PST
|
|
Location:
|
|
|
San Diego Convention Center, Hall GH
|
|
|
|
|
|
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small-molecule
drugs to treat patients afflicted with cancer and inflammatory diseases.
Our proprietary drug development pipeline includes clinical candidates
that are designed to regulate therapeutically important target proteins
and are aimed at significant unmet medical needs. For more information
on Array, please go to www.arraybiopharma.com.
Source: Array BioPharma
Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com
View printer-friendly version
